Evaluation of the response to an accelerated immunisation schedule using a canarypox-vectored equine influenza vaccine, shortened interdose intervals and vaccination of young foals.

The research evaluates the effectiveness of a quicker immunisation program intended to control and annihilate equine influenza in Australia in 2007. This faster program used a recombinant canarypox-vectored vaccine with a reduced time between doses and included horses as young as four months old.

Objective of the Study

• The primary objective of the research was to observe the outcome of an expedited immunisation plan applied during the emergency response to eradicate equine influenza outbreak in Australia in 2007.
• The research aims to understand if shorter intervals between vaccine doses and inclusion of younger foals in the vaccination process increased its effectiveness.

Methodology

• The researchers utilized a recombinant canarypox-vectored vaccine known as ProteqFlu®, provided by Merial.
• The interdose intervals, or the time between each vaccine dose, was shortened from the standard practice to administer the vaccine more rapidly.
• Notably, the vaccinated horses also included foals aged less than four months. This detail is significant as normally only older horses are vaccinated, given foals’ developing immune systems.

Implications of the Research

• The results from this study could provide insights and shape future emergency response plans and protocols for managing equine influenza outbreaks.
• If the research finds that the accelerated immunisation schedule is effective, it could lead to a policy change regarding vaccination schedules and the age at which horses are initially vaccinated.
• The results could also contribute to understanding on accelerated vaccination programs for other diseases and species, by giving insights into the efficacy and potential risks of shortening interdose intervals and vaccinating younger members of a population.